In Focus: Doing Business in Asia

| 01 February 2009 |  By 

Asia shines as a beacon of hope in an era when increasing development costs, shrinking pipelines, decreasing revenues and more-demanding clinical trials dominate discussions in the pharmaceutical industry. A recent report from the PricewaterhouseCooper's Health Research Institute,1 projects Asia to be the "Land of Golden Opportunities" that provides high-quality, inexpensive labor, and an increasingly favorable market for pharmaceuticals. Similar projections have been made by other financial and industry experts.2,3


© 2022 Regulatory Affairs Professionals Society.

Discover more of what matters to you

No taxonomy